VCM
IRON icon

Versant Capital Management’s Disc Medicine IRON Stock Holding History

Versant Capital Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19K Buy
30
+11
+58% +$756 ﹤0.01% 2553
2026
Q1 		$1.22K Hold
19
– – ﹤0.01% 2633
2025
Q4 		$1.51K Hold
19
– – ﹤0.01% 2481
2025
Q3 		$1.26K Hold
19
– – ﹤0.01% 2477
2025
Q2 		$1.01K Buy
+19
New +$892 ﹤0.01% 2487

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Versant Capital Management's IRON Position: Q2 2026 in Review

Versant Capital Management increased its Disc Medicine (IRON) stake by 58% in Q2 2026, buying an estimated $756 and bringing the position to 30 shares worth $2.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2553.

Versant Capital Management first reported a position in IRON in Q2 2025 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • Versant Capital Management held 30 shares of Disc Medicine worth $2.19K as of Q2 2026.
  • Versant Capital Management bought 11 Disc Medicine shares in Q2 2026, an estimated $756.
  • Disc Medicine made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2553 holding.
  • Versant Capital Management first reported a position in Disc Medicine in Q2 2025 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.